Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for depressive episode in bipolar II disorder
IRCT20160523028008N7Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in Bipolar II disorder (BP-II) and major depressive episode (MDE), sponsored by Hamadan University of Medical Sciences. Started Aug 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Bipolar II disorder (BP-II)major depressive episode (MDE)
Beyond the preview
Go deeper on IRCT20160523028008N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N7.